TRIP Sells Like It’s On Sale: Record‑Breaking Week of CBD Craze
Why everybody’s buzzing around the “drink‑worthy” CBD
TRIP has just posted the best week ever in sales after the recent spike in consumer faith in top‑tier CBD. The company, which is the fourth fastest‑growing private business in the UK (Sunday Times 100) and owns 88 % of the UK’s CBD‑drink market (Nielsen), is proving that quality really does pay off.
From a pause to a full‑on release
- Holland & Barrett briefly pulled their TRIP offerings last week, following a temporary FSA announcement.
- Now that the Food Standards Agency (FSA) and Trading Standards have cleared the brand with no changes needed to listings, formulas, labels or packaging, all TRIP products are back on shelves across 25 000 stores.
- TRIP had always championed regulation and compliance, and this swift lifting underscores their commitment to consumer safety.
FSA drops the 70 mg rule to just 10 mg – why TRIP says you’re on safe ground
Last week the FSA announced a new guideline of 10 mg per day, slashing the former limit of 70 mg. The agency said this stack is the lowest‑grade sample of CBD it tested. TRIP’s CBD, however, sits on a different tier.
Science says, “You’re safe”
- Independent lab tests – reviewed by the FSA – found TRIP’s CBD had a no observed adverse effect level (NOAEL) of 150 mg/kg body weight/day.
- That translates to a provisional daily intake of 105 mg, or about seven cans a day.
- To put that into perspective, the UK NHS guideline for the prescription drug Epidiolex (used for severe epilepsy) allows up to 1,750 mg per day for a 70 kg person.
- By contrast, Canada’s limit is 200 mg/day and the Netherlands’ is 160 mg/day—all far higher than the FSA’s latest 10 mg cut.
What the numbers are saying to shoppers
Following Mental Health Awareness Day (10 Oct) and the FSA upbeat tone, TRIP’s sales spiked to an all‑time high. The company highlighted that Britons continue to choose TRIP CBD to support day‑to‑day well‑being. The confidence comes after years of people having seen the benefits first‑hand.
TRIP’s Dominant Victory
- It topped the top 7 best‑selling CBD SKUs in the UK over the past year (Nielsen).
- With a 88 % share of the CBD‑drink market, TRIP is the clear leader.
Expert Take‑aways
Dr Julie Moltke, MD and CBD researcher, said: “It’s surprising that the FSA’s 10 mg guideline comes from a study of low‑grade samples—truly a misstep for high‑quality CBD.” She added that Canada’s and the Netherlands’ higher limits are far more in line with the safety data from TRIP’s products.
Dr Antonia Orsi, a toxicology specialist, confirmed the findings: “Our independent lab’s no‑observation threshold at 150 mg/kg body weight/day means the safe threshold is 105 mg per day. That’s a very reassuring figure for consumers.”
Bottom line: Feel good, drink good
TRIP isn’t just another CBD brand; it’s a market‑muscle leader backed by robust science and standing firm after FSA scrutiny. The company’s success says that high‑grade products win, and nobody’s going to relax until the next great wave of CBD‑drinks hits the shelves.
